Regulatory Roundup: FDA Expands Use of CSL's H1N1 Vaccine to Children, Approves Fifth H1N1 Vaccine...
ePT--the Electronic Newsletter of Pharmaceutical Technology
FDA has approved a fifth influenza A (H1N1) vaccine, manufactured by ID Biomedical.
The US Food and Drug Administration announced on Nov. 12, 2009, that it approved the use of the CSL’s (Melbourne, Australia) seasonal and influenza A (H1N1) vaccines to include children ages 6 months and older. These vaccines were previously approved for use in adults ages 18 years and older. “Because children are among those most vulnerable to the 2009 H1N1 virus, having a broader range of vaccines available for use in children is an important step in responding to the H1N1 outbreak,” Margaret A. Hamburg, commissioner of FDA, said in a press release. The vaccines will be available both in single-dose, preservative-free, prefilled syringes and in multidose vials that contain thimerosal, a mercury derivative, as a preservative.
In related news, FDA approved a fifth vaccine for protection against the influenza A (H1N1) virus. Manufactured by ID Biomedical (Quebec), which is owned by GlaxoSmithKline, the vaccine uses the “established, licensed egg-based manufacturing process used for producing seasonal flu vaccine,” according to an FDA release. ID Biomedical’s monovalent vaccine will be produced in multi-dose vials, in a formulation that contains thimerosal.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
